Literature DB >> 33915091

Laparoscopic versus open pancreatoduodenectomy for pancreatic or periampullary tumours: a multicentre, open-label, randomised controlled trial.

Min Wang1, Dewei Li2, Rufu Chen3, Xiaobing Huang4, Jing Li5, Yahui Liu6, Jianhua Liu7, Wei Cheng8, Xuemin Chen9, Wenxing Zhao10, Jingdong Li5, Zhijian Tan11, Heguang Huang12, Deyu Li2, Feng Zhu1, Tingting Qin1, Jingdong Ma13, Guangsheng Yu14, Baoyong Zhou15, Shangyou Zheng3, Yichen Tang4, Wei Han16, Lingyu Meng16, Jianji Ke16, Feng Feng17, Botao Chen8, Xinmin Yin8, Weibo Chen9, Hongqin Ma10, Jian Xu18, Yifeng Liu6, Ronggui Lin12, Yadong Dong19, Yahong Yu1, Jun Liu7, Hang Zhang1, Renyi Qin20.   

Abstract

BACKGROUND: The benefit and safety of laparoscopic pancreatoduodenectomy (LPD) for the treatment of pancreatic or periampullary tumours remain controversial. Studies have shown that the learning curve plays an important role in LPD, yet there are no randomised studies on LPD after the surgeons have surmounted the learning curve. The aim of this trial was to compare the outcomes of open pancreatoduodenectomy (OPD) with those of LPD, when performed by experienced surgeons.
METHODS: In this multicentre, open-label, randomised controlled trial done in 14 Chinese medical centres, we recruited patients aged 18-75 years with a benign, premalignant, or malignant indication for pancreatoduodenectomy. Eligible patients were randomly assigned (1:1) to undergo either LPD or OPD. Randomisation was centralised via a computer-generated system that used a block size of four. The patients and surgeons were unmasked to study group, whereas the data collectors, outcome assessors, and data analysts were masked. LPD and OPD were performed by experienced surgeons who had already done at least 104 LPD operations. The primary outcome was the postoperative length of stay. The criteria for discharge were based on functional recovery, and analyses were done on a modified intention-to-treat basis (ie, including patients who had a pancreatoduodenectomy regardless of whether the operation was the one they were assigned to). This trial is registered with Clinicaltrials.gov, number NCT03138213.
FINDINGS: Between May 18, 2018, and Dec 19, 2019, we assessed 762 patients for eligibility, of whom 656 were randomly assigned to either the LPD group (n=328) or the OPD group (n=328). 31 patients in each group were excluded and 80 patients crossed over (33 from LPD to OPD, 47 from OPD to LPD). In the modified intention-to-treat analysis (297 patients in the LPD group and 297 patients in the OPD group), the postoperative length of stay was significantly shorter for patients in the LPD group than for patients in the OPD group (median 15·0 days [95% CI 14·0-16·0] vs 16·0 days [15·0-17·0]; p=0·02). 90-day mortality was similar in both groups (five [2%] of 297 patients in the LPD group vs six [2%] of 297 in the OPD group, risk ratio [RR] 0·83 [95% CI 0·26-2·70]; p=0·76). The incidence rate of serious postoperative morbidities (Clavien-Dindo grade of at least 3) was not significantly different in the two groups (85 [29%] of 297 patients in the LPD group vs 69 [23%] of 297 patients in OPD group, RR 1·23 [95% CI 0·94-1·62]; p=0·13). The comprehensive complication index score was not significantly different between the two groups (median score 8·7 [IQR 0·0-26·2] vs 0·0 [0·0-20·9]; p=0·06).
INTERPRETATION: In highly experienced hands, LPD is a safe and feasible procedure. It was associated with a shorter length of stay and similar short-term morbidity and mortality rates to OPD. Nonetheless, the clinical benefit of LPD compared with OPD was marginal despite extensive procedural expertise. Future research should focus on identifying the populations that will benefit from LPD. FUNDING: National Natural Science Foundation of China and Tongji Hospital, Huazhong University of Science and Technology, China.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2021        PMID: 33915091     DOI: 10.1016/S2468-1253(21)00054-6

Source DB:  PubMed          Journal:  Lancet Gastroenterol Hepatol


  20 in total

Review 1.  [Surgical treatment of pancreatic cancer-What is new?]

Authors:  Thomas Schmidt; Orlin Belyaev; Waldemar Uhl; Christiane J Bruns
Journal:  Chirurg       Date:  2022-03-31       Impact factor: 0.955

2.  Minimally Invasive Pancreatoduodenectomy: Contemporary Practice, Evidence, and Knowledge Gaps.

Authors:  Jacob Ghotbi; Mushegh Sahakyan; Kjetil Søreide; Åsmund Avdem Fretland; Bård Røsok; Tore Tholfsen; Anne Waage; Bjørn Edwin; Knut Jørgen Labori; Sheraz Yaqub; Dyre Kleive
Journal:  Oncol Ther       Date:  2022-07-12

3.  Laparoscopic versus open surgery for hilar cholangiocarcinoma: a retrospective cohort study on short-term and long-term outcomes.

Authors:  Delin Ma; Wei Wang; Jianlei Wang; Tingxiao Zhang; Zhaochen Jiang; Gang Du; Jinhuan Yang; Xiqing Zhang; Guanjun Qin; Bin Jin
Journal:  Surg Endosc       Date:  2021-08-16       Impact factor: 3.453

4.  Robotic approach mitigates the effect of major complications on survival after pancreaticoduodenectomy for periampullary cancer.

Authors:  Thiagarajan Meyyappan; Greg C Wilson; Herbert J Zeh; Melissa E Hogg; Kenneth K Lee; Amer H Zureikat; Alessandro Paniccia
Journal:  Surg Endosc       Date:  2022-09-26       Impact factor: 3.453

5.  Comparing Minimally Invasive and Open Pancreaticoduodenectomy for the Treatment of Pancreatic Cancer: a Win Ratio Analysis.

Authors:  Eliza W Beal; Djhenne Dalmacy; Alessandro Paro; J Madison Hyer; Jordan Cloyd; Mary Dillhoff; Aslam Ejaz; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2022-06-15       Impact factor: 3.267

6.  Robotic pancreaticoduodenectomy after the learning curve-a new hope.

Authors:  Philip C Müller; Beat P Müller-Stich; Thilo Hackert; Felix Nickel
Journal:  Hepatobiliary Surg Nutr       Date:  2022-06       Impact factor: 8.265

7.  The Long-Term Outcome of Laparoscopic Resection for Perihilar Cholangiocarcinoma Compared with the Open Approach: A Real-World Multicentric Analysis.

Authors:  Tingting Qin; Min Wang; Hang Zhang; Jingdong Li; Xiaxing Deng; Yuhua Zhang; Wenxing Zhao; Ying Fan; Dewei Li; Xuemin Chen; Yechen Feng; Siwei Zhu; Zhongqiang Xing; Guangsheng Yu; Jian Xu; Junjie Xie; Changwei Dou; Hongqin Ma; Gangshan Liu; Yue Shao; Weibo Chen; Simiao Xu; Jun Liu; Jianhua Liu; Xinmin Yin; Renyi Qin
Journal:  Ann Surg Oncol       Date:  2022-10-22       Impact factor: 4.339

8.  Determining Hospital Volume Threshold for Safety of Minimally Invasive Pancreaticoduodenectomy: A Contemporary Cutpoint Analysis.

Authors:  Patricia C Conroy; Lucia Calthorpe; Joseph A Lin; Sarah Mohamedaly; Alex Kim; Kenzo Hirose; Eric Nakakura; Carlos Corvera; Julie Ann Sosa; Ankit Sarin; Kimberly S Kirkwood; Adnan Alseidi; Mohamed A Adam
Journal:  Ann Surg Oncol       Date:  2021-11-01       Impact factor: 4.339

9.  Laparoscopic versus open pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: study protocol for a multicentre randomised controlled trial.

Authors:  Shutao Pan; Tingting Qin; Taoyuan Yin; Xianjun Yu; Jing Li; Jun Liu; Wenxing Zhao; Xuemin Chen; Dewei Li; Jianhua Liu; Jingdong Li; Yahui Liu; Feng Zhu; Min Wang; Hang Zhang; Renyi Qin
Journal:  BMJ Open       Date:  2022-04-04       Impact factor: 2.692

Review 10.  [Surgery for periampullary pancreatic cancer].

Authors:  Thomas Hank; Ulla Klaiber; Klaus Sahora; Martin Schindl; Oliver Strobel
Journal:  Chirurg       Date:  2021-07-14       Impact factor: 0.955

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.